Teva launches generic Exjade
Teva is debuting a generic of Novartis' Exjade (deferasirox) tablets for oral suspension. The drug will be available in dosage strengths of 125 mg, 250 mg and 500 mg.
The product is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
“We’re proud to offer an affordable generic treatment option with the launch of deferasirox tablets for oral suspension in the U.S.,”, Teva executive vice president and head of North America commercial Brendan O’Grady said. “We continue striving to enable access to medicines for people living with chronic, complex conditions.”
Exjade had a market value of $134 million, according to December 2018 IQVIA data.
The product is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients two years of age and older.
“We’re proud to offer an affordable generic treatment option with the launch of deferasirox tablets for oral suspension in the U.S.,”, Teva executive vice president and head of North America commercial Brendan O’Grady said. “We continue striving to enable access to medicines for people living with chronic, complex conditions.”
Exjade had a market value of $134 million, according to December 2018 IQVIA data.